Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients.

The objective was to estimate the incidence of serious infections in the patients treated with anti-TNFalpha agents for rheumatoid arthritis (RA) recorded in the Lombardy Rheumatology Network (LORHEN) registry. The study inclusion criteria were met by 1064 of the 1114 patients with long-standing RA, 519 treated with infliximab, 303 with adalimumab, and 242 with etanercept; their mean age was 55.8 years and the mean duration of RA 9.4 years. Seventy-three patients (6.9%) experienced a total of 74 serious infections, an incidence rate for all treatment courses of 35.9 per 1000 patient-years (95% confidence interval [95% CI] 27.66-44.13). Most were lower respiratory tract (34.2%) or skin and soft tissue infections (20.5%). Of the 1064 patients, the 790 treated with anti-TNFalpha after March 2002 underwent screening tests for LTBI; five patients developed active tuberculosis. Three patients died of septic shock. The type of anti-TNFalpha agent did not seem to affect the incidence or site of the infections. Both univariate and multivariate analyses identified age at the start of anti-TNFalpha treatment (p=0.008), baseline erythrocyte sedimentation rate ([ESR] p=0.014), and the concomitant use of corticosteroids (p=0.029) as significant predictors of infections. There was no statistically significant difference in risk between the anti-TNFalpha agents.

[1]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[2]  D. Furst,et al.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002) , 2002, Annals of the rheumatic diseases.

[3]  G. Valesini,et al.  Biological and clinical effects of anti-TNFalpha treatment. , 2007, Autoimmunity reviews.

[4]  M. Hudson,et al.  Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. , 2007, Rheumatology.

[5]  M. Dougados,et al.  Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. , 2006, Rheumatology.

[6]  A. Silman,et al.  Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. , 2006, Arthritis and rheumatism.

[7]  N. McElvaney,et al.  Tumor Necrosis Factor– a –Converting Enzyme: Its Role in Community-Acquired Pneumonia , 2002 .

[8]  J. Gómez-Reino,et al.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.

[9]  D. Furst,et al.  Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study , 2005, Annals of the rheumatic diseases.

[10]  A. Silman,et al.  The British Society for Rheumatology Biologics Register. Ann Rheum Dis 2005;64 Suppl 4:iv42–3 , 2022 .

[11]  S. Sozzani,et al.  Inflammatory molecules: a target for treatment of systemic autoimmune diseases. , 2007, Autoimmunity reviews.

[12]  L. Zabraniecki,et al.  Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. , 2007, Seminars in arthritis and rheumatism.

[13]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[14]  D. Macdonald,et al.  Tumour necrosis factor alpha is pro‐inflammatory in normal human skin and modulates cutaneous adhesion molecule expression , 1995, The British journal of dermatology.

[15]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[16]  S. Ehlers,et al.  Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. , 2005, Seminars in arthritis and rheumatism.

[17]  Frederick Wolfe,et al.  Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. , 2006, Arthritis and rheumatism.

[18]  Matthias Schneider,et al.  Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.

[19]  M. Peterson,et al.  Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. , 2006, Respiratory medicine.

[20]  L. Klareskog,et al.  Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.

[21]  I. Iqbal,et al.  Safety and Efficacy of Disease-Modifying Anti-Rheumatic Agents , 2002, Drug safety.

[22]  A. Akdoğan,et al.  Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab , 2007, Scandinavian journal of infectious diseases.

[23]  R S Wallis,et al.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  A. Widmer,et al.  Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. , 2003, Rheumatology.

[25]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[26]  S. Ehlers.  Why does tumor necrosis factor targeted therapy reactivate tuberculosis? , 2005, The Journal of rheumatology. Supplement.

[27]  R. Long,et al.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. , 2003, The Lancet. Infectious diseases.

[28]  D. Furst,et al.  Safety of Tumour Necrosis Factor-α Antagonists , 2004 .

[29]  J. Baum.  Infection in rheumatoid arthritis. , 1971, Arthritis and rheumatism.

[30]  P. Sarzi-Puttini,et al.  Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). , 2011, Reumatismo.

[31]  J. Allison,et al.  Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. , 2007, Arthritis and rheumatism.

[32]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[33]  J. Sany,et al.  Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab. , 2005, The Journal of rheumatology.

[34]  S. Gabriel,et al.  Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. , 2002, Arthritis and rheumatism.

[35]  J. Gómez-Reino,et al.  Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. , 2005, Arthritis and rheumatism.